首页> 外文OA文献 >Safety and tolerability of a 'refrigeration-free' formulation of interferon beta-1b - Results of a double-blind, multicentre, comparative study in patients with relapsing-remitting or secondary progressive multipl sclerosis.

【2h】

Safety and tolerability of a 'refrigeration-free' formulation of interferon beta-1b - Results of a double-blind, multicentre, comparative study in patients with relapsing-remitting or secondary progressive multipl sclerosis.

机译：“无制冷”干扰素β-1b制剂的安全性和耐受性-复发缓解型或继发性进行性多发性硬化症患者的双盲，多中心，对比研究结果。

页面导航

著录项
相似文献
相关主题

著录项

作者
Baum K; Mannitol Formulation Study Group: Baumhackl U; Schautzer F; Seelrayers P; Moonen G; Dive D; Decoo D; (...); Trojano M; Bannermerschult R;
展开▼
作者单位

展开▼
年度 2006
总页数
原文格式 PDF
正文语种 eng
中图分类

相似文献

外文文献
中文文献
专利

1. Safety and Tolerability of a ‘Refrigeration-free’ Formulation of Interferon Beta-1b - Results of a Double-blind, Multicentre, Comparative Study in Patients with Relapsing-Remitting or Secondary Progressive Multiple Sclerosis [J] . K Baum, Mannitol Formulation Study Group Journal of International Medical Research . 2006,第1期

机译：“无制冷”干扰素β-1b制剂的安全性和耐受性-复发缓解型或继发性进行性多发性硬化症患者的双盲，多中心，对比研究结果
2. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study. [J] . Hurwitz BJ, Jeffery D, Arnason B, Clinical therapeutics . 2008,第6期

机译：复发缓解型多发性硬化症患者接受干扰素beta-1b 250 250和500微克QOD治疗12至28周的耐受性和安全性：一项多中心，随机，双盲，平行组先导研究。
3. A phase 2, 24-week, randomized, placebo-controlled, double-blind study examining the efficacy and safety of an anti-interleukin-12 and -23 monoclonal antibody in patients with relapsing-remitting or secondary progressive multiple sclerosis. [J] . Vollmer TL, Wynn DR, Alam MS, Multiple sclerosis: clinical and laboratory research . 2011,第2期

机译：2期，24周，随机，安慰剂对照，双盲研究，研究了抗白细胞介素12和-23单克隆抗体在复发缓解型或继发性进行性多发性硬化症患者中的疗效和安全性。
4. A Double-blind Comparative Study of Tebipenem Pivoxil in Pediatric Patients with Acute Otitis Media [C] . Suzuki K., Baba S., Ubukata K., Extraordinary International Symposium on Recent Advances in Otitis Media . 2009

机译：急性中耳炎患者Tebipenem Pivoxil的双盲对比研究
5. Population based cost utility study of interferon beta-1b in secondary progressive multiple sclerosis [O] . Raeburn B Forbes, Ann Lees, Norman Waugh, 1999

机译：继发性进行性多发性硬化症中干扰素β-1b的基于人群的成本效用研究
6. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. [O] . Paty, DW, Li, DK 1993

机译：干扰素beta-1b可有效缓解复发型多发性硬化症。二。一项多中心，随机，双盲，安慰剂对照试验的MRI分析结果。 UBC MS / MRI研究组和IFNB多发性硬化研究组。
7. Randomized Double-Blind Phase III Pivotal Field Trial of the Comparative Immunogenicity Safety and Tolerability of Two Yellow Fever 17D Vaccines (ARILVAX(Trademark) and YF-VAX(Trademark)) in Healthy Infants and Children in Peru [R] . Belmusto-Worn, V. E. , Sanchez, J. L. , McCarthy, K. , 2004

机译：秘鲁健康婴儿和儿童两种黄热病17D疫苗（aRILVaX（商标）和YF-VaX（商标））的比较免疫原性安全性和耐受性的随机双盲III期关键现场试验

Safety and tolerability of a 'refrigeration-free' formulation of interferon beta-1b - Results of a double-blind, multicentre, comparative study in patients with relapsing-remitting or secondary progressive multipl sclerosis.

著录项

相似文献

相关主题

期刊订阅